Theravance Biopharma, Inc. (NASDAQ: TBPH) has announced its participation in the upcoming 36th International Symposium on the Autonomic Nervous System. This event, organized by the American Autonomic Society (AAS), will take place from November 5 to 8, 2025, in Clearwater Beach, Florida.
During the symposium, Theravance will unveil a total of four presentations regarding its clinical development program for ampreloxetine. This drug is being investigated as a potential first-in-class norepinephrine reuptake inhibitor aimed at treating symptoms associated with neurogenic orthostatic hypotension (nOH) resulting from multiple system atrophy (MSA).
The presentations will include one platform talk and three poster sessions, highlighting significant advancements in the ongoing clinical trials of ampreloxetine. Notably, the company anticipates releasing topline results from its Phase 3 CYPRESS study in the first quarter of 2026.
This research is crucial as it addresses the needs of patients suffering from nOH, a condition that can significantly impair quality of life. By focusing on innovative therapeutic options like ampreloxetine, Theravance Biopharma aims to contribute to the understanding and treatment of this challenging syndrome.
The 36th International Symposium on the Autonomic Nervous System is a key gathering for experts in the field, providing a platform for sharing the latest research and developments in autonomic disorders. Theravance”s participation underscores its commitment to advancing therapeutic solutions that may improve patient outcomes in this area.
